Namocell Names New VP of Marketing and Business Development

Mountain View, Calif., (September 9, 2019) – Namocell Inc., a leading provider of single cell sorting and dispensing platforms, today announced that Abe Couse has joined the company’s management team as VP of Marketing and Business Development.

Abe brings over 20 years of life science commercial leadership experience in marketing, sales, business and product development, covering a wide range of genomics and proteomics platform technologies and capital equipment.  Abe is joining Namocell from Vium where he was VP of Product Development and led the commercial launch of the company’s digital in vivo testing platform which combines an on premise hardware solution with cloud computing and computer vision algorithms.  Prior to Vium, Abe served as VP of Life Sciences at Crown Bio where he led product development and marketing.  Before that, he served as Senior Director of Marketing at Epitomics where he led the commercial launch of Epitomics’ Rabbit Monoclonal Antibody product line.  While at Epitomics, he led the growth of the company’s product business from the ground up leading to an eventual successful acquisition by Abcam.  Earlier in his career, Abe held Product Management and Sales roles at BD Biosciences and Clontech.

“Namocell is revolutionizing single cell research and development.  Its innovative and versatile Namo and Hana single cell dispensers are the fastest on the market, and serve multiple fast-growing markets including single cell genomics, cell line development, CRISPR, cell therapy, monoclonal antibody development, rare cell isolation, and synthetic biology,” said Couse, “Namocell delivers unparalleled value to users by combining cutting edge technology and performance with ease of use.  I am really excited to join Namocell, and look forward to working with the team to bring our single cell dispensers to more researchers and scientists in both the academia and biotech industry.”

“We have expanded our global footprint in the past year with placements of our single cell dispensers in the hands of researchers and scientists around the world,” said Dr. Junyu Lin, CEO of Namocell.  “As we continue to provide more users with the fastest and easiest solution to isolate single cells, Abe’s extensive commercial leadership experience will help drive our continued success and growth.  We are very excited to welcome Abe to Namocell.”

About Namocell

Namocell is a leading provider of single cell sorting and dispensing platforms to advance single cell research and development.  By combining flow cytometry, microfluidics and liquid dispensing technologies, Namocell’s single cell dispensers provide the fastest and easiest way to identify and isolate single cells, and enable users to accomplish single cell sorting and dispensing in one step in a way that is gentle to live cells.  We serve researchers and scientists in a variety of applications, including single cell genomics, cell line development, CRISPR, cell therapy, monoclonal antibody development, rare cell isolation, and synthetic biology.  Learn more at www.namocell.com.